12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Tresiba: Extension study data

The open-label, international Phase III BEGIN ONCE LONG 1-year extension study of the Phase III BEGIN program in 725 Type II diabetics showed that patients receiving Tresiba reported significantly better scores on the HRQoL for overall physical health after 2 years vs. Lantus...

Read the full 204 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >